Publicaciones en colaboración con investigadores/as de Hospital Universitario de Salamanca (14)

2023

  1. Key Factors Associated With Pulmonary Sequelae in the Follow-Up of Critically Ill COVID-19 Patients

    Archivos de Bronconeumologia, Vol. 59, Núm. 4, pp. 205-215

2022

  1. Major candidate variables to guide personalised treatment with steroids in critically ill patients with COVID-19: CIBERESUCICOVID study

    Intensive Care Medicine, Vol. 48, Núm. 7, pp. 850-864

  2. Prognostic Value of Serum Paraprotein Response Kinetics in Patients With Newly Diagnosed Multiple Myeloma

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 22, Núm. 9, pp. e844-e852

  3. Therapeutic versus Prophylactic Bemiparin in Hospitalized Patients with Nonsevere COVID-19 Pneumonia (BEMICOP Study): An Open-Label, Multicenter, Randomized, Controlled Trial

    Thrombosis and Haemostasis, Vol. 122, Núm. 2, pp. 295-299

2021

  1. Deploying unsupervised clustering analysis to derive clinical phenotypes and risk factors associated with mortality risk in 2022 critically ill patients with COVID-19 in Spain

    Critical Care, Vol. 25, Núm. 1

2019

  1. A precision medicine test predicts clinical response after idarubicin and cytarabine induction therapy in AML patients

    Leukemia Research, Vol. 76, pp. 1-10

2018

  1. Limitation of life support techniques at admission to the intensive care unit: A multicenter prospective cohort study

    Journal of Intensive Care, Vol. 6, Núm. 1

2016

  1. Delay in diagnosis of influenza A (H1N1)pdm09 virus infection in critically ill patients and impact on clinical outcome

    Critical Care, Vol. 20, Núm. 1

2014

  1. Pharmacological profiles of acute myeloid leukemia treatments in patient samples by automated flow cytometry: A bridge to individualized medicine

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 14, Núm. 4, pp. 305-318

2011

  1. Pharmacokinetic monitoring of antiepileptic drugs

    Farmacia Hospitalaria

2010

  1. In vitro and in vivo selective antitumor activity of edelfosine against mantle cell lymphoma and chronic lymphocytic leukemia involving lipid rafts

    Clinical Cancer Research, Vol. 16, Núm. 7, pp. 2046-2054

  2. Lipid raft-targeted therapy in multiple myeloma

    Oncogene, Vol. 29, Núm. 26, pp. 3748-3757

2009

  1. Antitumor alkyl ether lipid edelfosine: Tissue distribution and pharmacokinetic behavior in healthy and tumor-bearing immunosuppressed mice

    Clinical Cancer Research, Vol. 15, Núm. 3, pp. 858-864

2008

  1. Recomendaciones para la monitorización de antibióticos en pacientes críticos ingresados en UCI

    Enfermedades Infecciosas y Microbiologia Clinica